Seres Therapeutics Inc. has reported its financial results for the second quarter of 2025. The company experienced a net loss from continuing operations of $19.9 million, which is an improvement compared to a net loss of $26.2 million for the same period in 2024. Research and development expenses also decreased to $12.9 million in the second quarter of 2025 from $15.8 million in the same period of the previous year. This reduction was largely attributed to a decrease in expenses following the completion of the SER-155 Phase 1b study, reduced personnel and related expenses, and lower platform investments. In terms of business updates, Seres has submitted a Phase 2 study protocol to the FDA for SER-155, aimed at preventing bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant to treat hematological malignancies. The company is actively exploring various deal structures, including partnerships and mergers, to secure capital for the clinical advancement of SER-155 and other live biotherapeutic product candidates. Additionally, Seres received a $25 million installment payment from Nestlé Health Science in July 2025. The company expects to fund its operations into the first quarter of 2026, following cost reduction actions aimed at extending its cash runway.